Skip to main content
Top
Published in: Journal of General Internal Medicine 2/2013

01-02-2013 | Original Research

Confounding in the Association of Proton Pump Inhibitor Use With Risk of Community-Acquired Pneumonia

Authors: Anupam B. Jena, MD, PhD, Eric Sun, MD,PhD, Dana P. Goldman, PhD

Published in: Journal of General Internal Medicine | Issue 2/2013

Login to get access

ABSTRACT

BACKGROUND

Use of proton pump inhibitors (PPIs) is associated with community-acquired pneumonia (CAP), an association which may be confounded by unobserved patient and prescriber characteristics.

OBJECTIVE

We assessed for confounding in the association between PPI use and CAP by using a ‘falsification approach,’ which estimated whether PPI use is also implausibly associated with other common medical conditions for which no known pathophysiologic link exists.

DESIGN

Retrospective claims-based cohort study.

SETTING

Six private U.S. health plans.

SUBJECTS

Individuals who filled at least one prescription for a PPI (N = 26,436) and those who never did (N = 28,054) over 11 years.

INTERVENTIONS

Multivariate linear regression of the association between a filled prescription for a PPI and a diagnosis of CAP in each 3-month quarter. In falsification analyses, we tested for implausible associations between PPI use in each quarter and rates of osteoarthritis, chest pain, urinary tract infection (UTI), deep venous thrombosis (DVT), skin infection, and rheumatoid arthritis. Independent variables included an indicator for whether a prescription for a PPI was filled in a given quarter, and quarterly indicators for various co-morbidities, age, income, geographic location, and marital status.

KEY RESULTS

Compared to nonusers, those ever using a PPI had higher adjusted rates of CAP in quarters in which no prescription was filled (68 vs. 61 cases per 10,000 persons, p < 0.001). Similar associations were noted for all conditions (e.g. chest pain, 336 vs. 282 cases, p < 0.001; UTI, 151 vs. 139 cases, p < 0.001). Among those ever using a PPI, quarters in which a prescription was filled were associated with higher adjusted rates of CAP (111 vs. 68 cases per 10,000, p < 0.001) and all other conditions (e.g. chest pain, 597 vs. 336 cases, p < 0.001; UTI, 186 vs. 151 cases, p < 0.001), compared to quarters in which no prescription was filled.

CONCLUSION

PPI use is associated with CAP, but also implausibly associated with common medical conditions. Observed associations between PPI use and CAP may be confounded.
Appendix
Available only for authorised users
Literature
1.
go back to reference Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–1960.PubMedCrossRef Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–1960.PubMedCrossRef
2.
go back to reference Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–398.PubMed Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149(6):391–398.PubMed
3.
go back to reference Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch Intern Med. 2007;167(9):950–955.PubMedCrossRef Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case–control study. Arch Intern Med. 2007;167(9):950–955.PubMedCrossRef
4.
go back to reference Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut. 1987;28(1):96–107.PubMedCrossRef Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut. 1987;28(1):96–107.PubMedCrossRef
5.
go back to reference Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med. 1973;78(2):271–276.PubMed Giannella RA, Broitman SA, Zamcheck N. Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med. 1973;78(2):271–276.PubMed
6.
go back to reference Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. 1980;1(8170):672–674.PubMed Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet. 1980;1(8170):672–674.PubMed
7.
go back to reference IMS. Leading Therapy Classes in 2002 Global Pharmaceutical Sales. IMS World Review. Vol. 2010; 2010. IMS. Leading Therapy Classes in 2002 Global Pharmaceutical Sales. IMS World Review. Vol. 2010; 2010.
8.
go back to reference Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139(4):1115–1127.PubMedCrossRef Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139(4):1115–1127.PubMedCrossRef
9.
go back to reference Logan IC, Sumukadas D, Witham MD. Gastric acid suppressants–too much of a good thing? Age and ageing. 2010;39(4):410–411.PubMedCrossRef Logan IC, Sumukadas D, Witham MD. Gastric acid suppressants–too much of a good thing? Age and ageing. 2010;39(4):410–411.PubMedCrossRef
10.
go back to reference Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2010;24(2):193–201.PubMedCrossRef Lodato F, Azzaroli F, Turco L, et al. Adverse effects of proton pump inhibitors. Best Pract Res Clin Gastroenterol. 2010;24(2):193–201.PubMedCrossRef
11.
go back to reference Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case–control study. Ann Intern Med. 2010;152(7):418–25, W139-40. Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case–control study. Ann Intern Med. 2010;152(7):418–25, W139-40.
12.
go back to reference Popper KR. The Logic of Scientific Discovery Routledge; 2002. Popper KR. The Logic of Scientific Discovery Routledge; 2002.
13.
go back to reference Heckman JJ, Hotz VJ. Choosing among alternative nonexperimental methods for estimating the impact of social programs: the case of manpower training. J Am Stat Assoc. 1989;84(408):862–874.CrossRef Heckman JJ, Hotz VJ. Choosing among alternative nonexperimental methods for estimating the impact of social programs: the case of manpower training. J Am Stat Assoc. 1989;84(408):862–874.CrossRef
14.
go back to reference Bertrand M, Duflo E, Mullainathan S. How much should We trust differences-in-differences estimates? Q J Econ. 2004;119(1):249–275.CrossRef Bertrand M, Duflo E, Mullainathan S. How much should We trust differences-in-differences estimates? Q J Econ. 2004;119(1):249–275.CrossRef
15.
go back to reference Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733–1739.PubMedCrossRef Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733–1739.PubMedCrossRef
16.
go back to reference Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319–1331.CrossRef Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. Benefit design and specialty drug use. Health Aff (Millwood). 2006;25(5):1319–1331.CrossRef
17.
go back to reference Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344–2350.PubMedCrossRef Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344–2350.PubMedCrossRef
18.
go back to reference Solomon MD, Goldman DP, Joyce GF, Escarce JJ. Cost sharing and the initiation of drug therapy for the chronically ill. Arch Intern Med. 2009;169(8):740–748. discussion 748–9.PubMedCrossRef Solomon MD, Goldman DP, Joyce GF, Escarce JJ. Cost sharing and the initiation of drug therapy for the chronically ill. Arch Intern Med. 2009;169(8):740–748. discussion 748–9.PubMedCrossRef
19.
go back to reference Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S–13S.PubMedCrossRef Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002;113(Suppl 1A):5S–13S.PubMedCrossRef
20.
go back to reference Ellis Simonsen SM, van Orman ER, Hatch BE, et al. Cellulitis incidence in a defined population. Epidemiol Infect. 2006;134(2):293–299.PubMedCrossRef Ellis Simonsen SM, van Orman ER, Hatch BE, et al. Cellulitis incidence in a defined population. Epidemiol Infect. 2006;134(2):293–299.PubMedCrossRef
21.
go back to reference United States Department of H, Human Services. Centers for Disease C, Prevention. National Center for Health S. National Ambulatory Medical Care Survey, 2009. Inter-university Consortium for Political and Social Research (ICPSR) [distributor]; 2011. United States Department of H, Human Services. Centers for Disease C, Prevention. National Center for Health S. National Ambulatory Medical Care Survey, 2009. Inter-university Consortium for Political and Social Research (ICPSR) [distributor]; 2011.
22.
go back to reference Ware JH, Dockery DW, Louis TA, Xu XP, Ferris BG Jr, Speizer FE. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol. 1990;132(4):685–700.PubMed Ware JH, Dockery DW, Louis TA, Xu XP, Ferris BG Jr, Speizer FE. Longitudinal and cross-sectional estimates of pulmonary function decline in never-smoking adults. Am J Epidemiol. 1990;132(4):685–700.PubMed
23.
go back to reference Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8(5):571–574.PubMedCrossRef Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8(5):571–574.PubMedCrossRef
24.
go back to reference Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case–control study. BMJ. 1996;312(7028):414–415.PubMedCrossRef Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case–control study. BMJ. 1996;312(7028):414–415.PubMedCrossRef
25.
go back to reference Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ. 2004;171(1):33–38.PubMedCrossRef Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ. 2004;171(1):33–38.PubMedCrossRef
26.
go back to reference Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent clostridium difficile infection. Arch Intern Med. 2010;170(9):772–778.PubMedCrossRef Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent clostridium difficile infection. Arch Intern Med. 2010;170(9):772–778.PubMedCrossRef
27.
go back to reference Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–2953.PubMedCrossRef Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–2953.PubMedCrossRef
28.
go back to reference Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med. 2007;357(4):370–379.PubMedCrossRef Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med. 2007;357(4):370–379.PubMedCrossRef
29.
go back to reference Cohen-Cole E, Fletcher JM. Detecting implausible social network effects in acne, height, and headaches: longitudinal analysis. BMJ. 2008;337:a2533.PubMedCrossRef Cohen-Cole E, Fletcher JM. Detecting implausible social network effects in acne, height, and headaches: longitudinal analysis. BMJ. 2008;337:a2533.PubMedCrossRef
Metadata
Title
Confounding in the Association of Proton Pump Inhibitor Use With Risk of Community-Acquired Pneumonia
Authors
Anupam B. Jena, MD, PhD
Eric Sun, MD,PhD
Dana P. Goldman, PhD
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 2/2013
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-012-2211-5

Other articles of this Issue 2/2013

Journal of General Internal Medicine 2/2013 Go to the issue

Healing Arts: Materia Medica

Haunted by the Unread

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.